Chris Cooley
Stock Analyst at Stephens & Co.
(3.10)
# 1,012
Out of 4,667 analysts
57
Total ratings
69.44%
Success rate
48.28%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $56.71 | -25.94% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $228.21 | +64.32% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $99.91 | +15.10% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $85.57 | +7.51% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $16.12 | -25.56% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $17.43 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $42.61 | +111.22% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $215.77 | +25.13% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $140.83 | -51.71% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $18.02 | +149.72% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $190.64 | +44.25% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $26.63 | +38.94% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $74.46 | -19.42% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $15 | $0.32 | +4,646.84% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $91.50 | -61.75% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $262.00 | -69.08% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $56.71
Upside: -25.94%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $228.21
Upside: +64.32%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $99.91
Upside: +15.10%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $85.57
Upside: +7.51%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $16.12
Upside: -25.56%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $17.43
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $42.61
Upside: +111.22%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $215.77
Upside: +25.13%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $140.83
Upside: -51.71%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $18.02
Upside: +149.72%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $190.64
Upside: +44.25%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $26.63
Upside: +38.94%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $74.46
Upside: -19.42%
Mar 23, 2020
Maintains: Overweight
Price Target: $45 → $15
Current: $0.32
Upside: +4,646.84%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $91.50
Upside: -61.75%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $262.00
Upside: -69.08%